Monocarboxylate transporter 1 inhibitors as potential anticancer agents.

ACS Med Chem Lett

Integrated Biosciences Graduate Program, Department of Chemistry and Biochemistry, Department of Biomedical Sciences, Medical School Duluth, and Department of Pharmacy Practice & Pharmaceutical Sciences, University of Minnesota Duluth, Duluth, Minnesota 55812, United States.

Published: May 2015

Potent monocarboxylate transporter 1 inhibitors (MCT1) have been developed based on α-cyano-4-hydroxycinnamic acid template. Structure-activity relationship studies demonstrate that the introduction of p-N, N-dialkyl/diaryl, and o-methoxy groups into cyanocinnamic acid has maximal MCT1 inhibitory activity. Systemic toxicity studies in healthy ICR mice with few potent MCT1 inhibitors indicate normal body weight gains in treated animals. In vivo tumor growth inhibition studies in colorectal adenocarcinoma (WiDr cell line) in nude mice xenograft models establish that compound 27 exhibits single agent activity in inhibiting the tumor growth.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4434469PMC
http://dx.doi.org/10.1021/acsmedchemlett.5b00049DOI Listing

Publication Analysis

Top Keywords

monocarboxylate transporter
8
transporter inhibitors
8
tumor growth
8
inhibitors potential
4
potential anticancer
4
anticancer agents
4
agents potent
4
potent monocarboxylate
4
inhibitors mct1
4
mct1 developed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!